AiM - Reimbursement

AiM has been helping the medical devices industry in getting access to the German market. Our guide explains the basic principles of the German reimbursement system and gives an overview of the German market and healthcare system.

  • AiM supports medical device manufacturers
    in all aspects of reimbursement
  • AiM's comprehensive approach has helped
    more than 250 companies grow
  • AiM – assistants for commercializing medical
    devices in Germany

Our main focus is on

  • reimbursement and pricing analyses,
  • market access consulting,
  • appraisal of clinical evidence and safety and support for study designs.

Since 2007, AiM has supported the medical device industry. We help medical device manufacturers access the German and other leading markets in Europe. To date, we have completed more than 800 projects for more than 250 clients.

We analyze product potentials. We identify correct reimbursement pathways. We speed up reimbursement and product launch. We identify distribution channels and assess local distributors.

Services

We help medical device manufacturers bring their products to
European markets quickly and optimally:

Strategic Consulting for Germany
and Europe

  • Pricing and market access
  • Portrayal of individual product reimbursement pathways
  • Assistance with review processes conducted by the German Federal Joint Committee (G-BA) and other European health authorities
  • Distribution strategies

Health Economics &
Outcomes Research

  • Value demonstration
  • Health Technology Assessment (HTA)
  • Reimbursement Applications

Real-world and Care Provision
Analysis

  • Treatment cost analyses
  • Hospital data analyses in cooperation with IMC clinicon

Market Analysis

  • Assessment of inpatient and ambulatory sector potentials
  • Competition and regulation analysis
  • European market entry strategies
  • Evaluation of distribution pathways

Clinical Trials

Reimbursement of Digital Health Apps

  • Market access and reimbursement
  • Support for inclusion in the DiGA directory
  • Assessment of alternative reimbursement pathways outside the DVG (Digitales-Versorgungs-Gesetz)
 

Visit Us On LinkedIn

Investment
Investment
Respiratory
Respiratory
Cardiovascular
Cardiovascular
Urology
Urology
Cardiovascular
Cardiovascular
Osteoarthritis
Osteoarthritis
Cardiovascular
Cardiovascular
Cardiovascular
Cardiovascular
Oncology
Oncology
Cardiovascular
Cardiovascular
Oncology
Oncology
Cardiovascular
Cardiovascular
Cardiovascular
Cardiovascular
Orthopaedics
Orthopaedics
Gynaecology
Gynaecology
Patient_monitoring
Patient_monitoring
Cardiovascular
Cardiovascular
Gastroenterology
Gastroenterology
Orthopaedics
Orthopaedics
Gastroenterology
Gastroenterology
Cardiovascular
Cardiovascular
Diagnostics
Diagnostics
Oncology
Oncology
Orthopaedics
Orthopaedics
Cardiovascular
Cardiovascular
Cardiovascular
Cardiovascular
Orthopaedics
Orthopaedics
Psychiatry
Psychiatry
Respiratory
Respiratory
Imaging
Imaging
Cardiovascular
Cardiovascular
Surgery
Surgery
Ophthalmology
Ophthalmology
Medical Nutrition
Medical Nutrition
Neurology
Neurology
Ophthalmology
Ophthalmology
Cardiovascular
Cardiovascular
Orthopaedics
Orthopaedics
Urology
Urology
Oncology
Oncology
Dermatology
Dermatology
Gynaecology
Gynaecology
Cardiovascular
Cardiovascular
Orthopaedics
Orthopaedics
Respiratory
Respiratory
Orthopaedics
Orthopaedics
Orthopaedics
Orthopaedics
Dermatology
Dermatology
Respiratory
Respiratory
Oncology
Oncology
Diabetes
Diabetes
Oncology
Oncology
Cardiovascular
Cardiovascular
Consultant
Consultant
Cardiovascular
Cardiovascular
Cardiovascular
Cardiovascular
Cardiovascular
Cardiovascular
Cardiovascular
Cardiovascular
Consultant
Consultant
Respiratory
Respiratory
Oncology
Oncology
Ophthalmology
Ophthalmology
Cardiovascular
Cardiovascular
Ophthalmology
Ophthalmology
Cardiovascular
Cardiovascular
Respiratory
Respiratory